The real data tells you: How does the centralized drug compare to the original research drug?

Text | Yang Zi

Since 2018, the National Medical Insurance Administration has successively launched four batches of national drug centralized procurement, involving a total of 157 varieties and 533 selected products.

1.

Based on the indications and dosage form characteristics of the first batch of successful bidding drugs purchased in quantity, this study focuses on the treatment of cardiovascular and cerebrovascular diseases (antiplatelet, blood pressure, and lipid-lowering) drugs, and the treatment of neuropsychiatric diseases (depression, schizophrenia, epilepsy) There are five major categories of drugs, chronic hepatitis B treatment drugs, anti-tumor drugs, and injections.

2.

After confirming the samples, the research team selected targeted evaluation indicators based on the clinical guidelines and the big data of the hospital information system to conduct a comparative study on the original research drug and the collectively collected generic drugs: effectiveness indicators such as blood pressure, blood lipids, and viral serum Conversion rate, clinical remission rate, etc.

3.

Taking Entecavir as an example, a study of 35,450 patient data shows that the generic drug Entecavir is effective in treating hepatitis B patients (complete virological response rate, virological breakthrough rate, HBeAg seroconversion rate, HBeAg negative rate, and ALT return Compared with the original drug, there is no statistical difference in the incidence of adverse reactions (increased blood creatinine rate, increased blood creatine enzyme rate and thrombocytopenia rate), and the compliance is better.

There are also some generic drugs that even perform better than the original drugs in terms of adverse reactions.

It can be said that the massive and real clinical data used in this study proved that the generic drugs collected in my country are effective and safe, and there is no difference in clinical application from the original drugs.

4.

At the same time, we may also wish to change our thinking and concepts, keep our eyes on the ground, and accept the mentality of "looking up" towards the original research drug.

It is a fact that my country's drug research and development started late, but the late start does not mean that it will always be behind.

In recent years, the state has promoted innovation and strengthened supervision through various means, and the effectiveness and safety of medicines have been guaranteed, which can well meet the needs of patients.
More use of cheap, high-quality centralized procurement of generic drugs, patients save money, hospitals have a balance, medical insurance also saves money, the tripartite profits, why not do it?